Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for advanced lung cancer: experimental drug DS-1062a takes on standard chemo

NCT ID NCT04656652

Disease control Sponsor: Daiichi Sankyo Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 27, 2026 · Updated 3 times

Summary

This study compares a new drug, DS-1062a, to the standard chemotherapy docetaxel in about 600 adults with advanced or metastatic non-small cell lung cancer that has worsened after previous treatment. The goal is to see if DS-1062a can slow cancer growth or extend survival better than docetaxel. Participants must have a life expectancy of at least 3 months and meet other health criteria.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

605 people

The number who actually took part.

Started

Dec 2020

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Participants eligible for inclusion in the study must meet all inclusion criteria within 28 days of randomization into the study. * Sign and date the inform consent form (ICF) prior to the start of any study specific qualification procedures. * Adults ≥18 years (if the legal age of consent is \>18 years old, then follow local regulatory requirements) * Life expectancy ≥3 months * Has pathologically documented Stage IIIB, IIIC, or stage IV NSCLC disease with or without actionable genomic alterations (AGA) at the time of randomization (based on the American Joint Committee on Cancer, Eighth Edition) and meets following criteria for NSCLC: * Participants without AGA: 1. Must have documented negative test results for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK). 2. Must have no known genomic alterations in ROS proto-oncogene 1 (ROS1), neurotrophic tyrosine receptor kinase (NTRK), proto oncogene B-raf (BRAF), mesenchymal-epithelial transition (MET) exon 14 skipping, or rearranged during transfection (RET). * Participants with AGA must have one or more documented actionable genomic alteration(s): EGFR, ALK, ROS1, NTRK, BRAF, MET exon 14 skipping, or RET. * Has documentation of radiographic disease progression while on or after receiving the most recent treatment regimen for advanced or metastatic NSCLC. * Participant without AGA must meet 1 of the following prior therapy requirements for advanced or metastatic NSCLC: 1. Received platinum-based chemotherapy in combination with α-PD-1/α-PD-L1 monoclonal antibody as the only prior line of therapy. * Includes participants who received prior platinum-based/chemotherapy with or without radiotherapy with maintenance α-PD-1/α-PD-L1 monoclonal antibody for Stage III disease and relapsed/progressed within 6 months from the last dose of platinum-based chemotherapy. * Includes participants who received prior platinum-based/chemotherapy with or without radiotherapy (with or without maintenance α-PD-1/α-PD-L1 monoclonal antibody) for Stage III disease and subsequently received α-PD-1/α-PD-L1 monoclonal antibody therapy (with or without platinum-based chemotherapy) for recurrent disease. 2. Received platinum-based chemotherapy and α-PD-1/α-PD-L1 monoclonal antibody (in either order) sequentially as the only 2 prior lines of therapy. * Participants with AGA must meet the following for advanced or metastatic NSCLC: 1. Participants who have been treated with 1 or 2 prior lines of applicable targeted therapy that is locally approved for the participant's genomic alteration at the time of screening; * Participants who have tumors with EGFR L858R or exon 19 deletion mutations must have received prior Osimertinib. * Those who received a targeted agent as adjuvant therapy for early-stage disease must have relapsed or progressed while on the treatment or within 6 months of the last dose OR received at least one additional course of targeted therapy for the same genomic alteration (which may or may not be same agent used in the adjuvant setting) for relapsed/progressive disease. * Participants who have been treated with a prior tyrosine kinase inhibitor (TKI ) must receive additional approved targeted therapy, if locally available and clinically appropriate, for the applicable genomic alteration, or the participant will not be allowed in the study. 2. Participants who have received platinum-based chemotherapy as the only prior line of cytotoxic therapy: * One platinum-containing regimen for advanced disease * Those who received a platinum-containing regimen as adjuvant therapy for early-stage disease must have relapsed or progressed while on the treatment or within 6 months of the last dose OR received at least one additional course of platinum-containing therapy (which may or may not be same as in the adjuvant setting) for relapsed/progressive disease. 3. May have received up to one α-PD-1/α-PD-L1 monoclonal antibody alone or in combination with a cytotoxic agent. * Must undergo a pre-treatment tumor biopsy procedure or if available, tumor tissue previously retrieved from a biopsy procedure performed within 2 years prior to the participant signing informed consent and that has a minimum of 10 × 4 micron sections or a tissue block equivalent of 10 × 4 micron sections may be substituted for the pre-treatment biopsy procedure during Screening. If a documented law or regulation prohibits (or does not approve) sample collection, then such samples will not be collected/submitted * Measurable disease based on local imaging assessment using RECIST v1.1 * Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1 at Screening * Within 7 days before randomization, has adequate bone marrow, hepatic, and renal function * Left ventricular ejection fraction (LVEF) ≥50% by either echocardiogram (ECHO) or multigated acquisition (MUGA) scan within 28 days before randomization * Adequate blood clotting function defined as international normalized ratio/prothrombin time and either partial thromboplastin or activated partial thromboplastin time ≤1.5 × upper limit of normal (ULN) * Adequate treatment washout period before randomization * Females of childbearing potential must have a negative serum pregnancy test at screening and must be willing to use highly effective birth control from the time of enrollment up to 7 months after the last dose of DS-1062a or for at least 6 months after the last dose of docetaxel * Males must be surgically sterile or must use a condom in addition to highly effective birth control if his partners are of reproductive potential from the time of enrollment and for at least 4 months after last dose of DS-1062a or for at least 6 months after the last dose of docetaxel * Male participants must not freeze or donate sperm from the time of Screening and throughout the study period and for at least 4 months after the last dose of DS-1062a or for at least 6 months after the last dose of docetaxel * Female participants must not donate, or retrieve for their own use, ova from the time of Screening and throughout the study period and for at least 7 months after the last dose of DS-1062a and for at least 6 months after the last dose of docetaxel Exclusion Criteria: * Mixed small-cell lung cancer (SCLC) and NSCLC histology * Has spinal cord compression or clinically active central nervous system metastases, defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms. Participants with clinically inactive brain metastases may be included in the study. Participants with treated brain metastases who are no longer symptomatic and who require no treatment with corticosteroids or anticonvulsants may be included in the study if they have recovered from the acute toxic effect of radiotherapy. * Has leptomeningeal carcinomatosis or metastasis * Had prior treatment with: * Any agent including antibody drug conjugate (ADC) containing a chemotherapeutic agent targeting topoisomerase I * TROP2-targeted therapy * Docetaxel * Had prior treatment with platinum-based chemotherapy and prior immunotherapy for Stage II NSCLC disease (eg, in the neo-adjuvant or adjuvant setting) without subsequently meeting the prior therapy requirements for Stage III or metastatic NSCLC disease * Has NSCLC disease that is eligible for definitive local therapy alone * Has uncontrolled or significant cardiac disease, including: * Mean QT interval corrected for heart rate using Fridericia's formula \>470 msec (based on the average of Screening triplicate 12-lead electrocardiogram \[ECG\] determinations). * Myocardial infarction or uncontrolled/unstable angina within 6 months before randomization * Congestive heart failure (CHF) (New York Heart Association Class II to IV) at Screening. Participants with a history of Class II to IV CHF prior to Screening, must have returned to Class I CHF and have LVEF ≥50% (by either an ECHO or MUGA scan within 28 days before randomization) in order to be eligible. * Uncontrolled or significant cardiac arrhythmia * LVEF \<50% by ECHO or MUGA scan within 28 days before randomization * Uncontrolled hypertension (resting systolic blood pressure \>180 mmHg or diastolic blood pressure \>110 mmHg) within 28 days before randomization * Has a history of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at Screening * Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder (ie, pulmonary emboli within 3 months before randomization, severe asthma, severe chronic obstructive pulmonary disease, restrictive lung disease, pleural effusion, etc.), or any autoimmune, connective tissue or inflammatory disorders with pulmonary involvement (ie, rheumatoid arthritis, Sjogren's syndrome, sarcoidosis, etc.), or prior pneumonectomy. * Significant third-space fluid retention (for example ascites or pleural effusion) and is not amenable for required repeated drainage * Clinically significant corneal disease * Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals; suspected infections (eg, prodromal symptoms); or inability to rule out infections * Has known human immunodeficiency virus (HIV) infection that is not well controlled * Has an active or uncontrolled hepatitis B and/or hepatitis C infection, is positive for hepatitis B or C virus based on the evaluation of results of tests for hepatitis B (hepatitis B surface antigen \[HBsAg\], anti-hepatitis B surface antibody \[anti-HBs\], anti-hepatitis B core antibody \[anti-HBc\], or hepatitis B virus \[HBV\] DNA), and/or hepatitis C infection (as per hepatitis C virus \[HCV\] RNA) within 28 days of randomization. * Has a history of malignancy, other than NSCLC, except adequately resected non-melanoma skin cancer, curatively treated in situ disease, or other solid tumors curatively treated, with no evidence of disease for ≥3 years * Toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet improved to NCI-CTCAE version 5.0 Grade ≤1 or baseline * Has a history of severe hypersensitivity reactions to either the drug substances, inactive ingredients (including but not limited to polysorbate 80) of DS-1062a or docetaxel, or monoclonal antibodies * Pregnant or breastfeeding * Has substance abuse or any other medical conditions such as clinically significant cardiac or psychological conditions

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-small cell lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-small cell lung cancer

Contacts and locations

Locations

  • APHM - Hopital Nord

    Marseille, 13915, France

  • ASL 3 Genovese Oncologia Medica Villa Scassi

    Genova, 16149, Italy

  • Affiliated Cancer Hospital of Xinjiang Medical University

    Ürümqi, China

  • American Oncology Partners of Maryland

    Bethesda, Maryland, 20817, United States

  • Amphia Ziekenhuis

    Breda, 4818 CK, Netherlands

  • Asan Medical Center

    Seoul, 05505, South Korea

  • Asklepios Fachklinik Muenchen-Gauting

    Gauting, 82131, Germany

  • Astera Cancer Care

    Somerset, New Jersey, 08873, United States

  • Austin Hospital

    Heidelberg, 03084, Australia

  • Avera Cancer Institute

    Sioux Falls, South Dakota, 57105, United States

  • Azienda Ospedaliera Universitaria Policlinico G Rodolico San Marco

    Catania, 95030, Italy

  • Azienda Ospedaliero- Universitaria Policlinico S. Orsola-Malpighi

    Bologna, 40138, Italy

  • Azienda Ospedaliero-Universitaria San Luigi Gonzaga

    Orbassano, 10043, Italy

  • Baptist Health Louisville

    Louisville, Kentucky, 40207, United States

  • Baton Rouge General

    Baton Rouge, Louisiana, 70809, United States

  • Beijing Cancer Hospital

    Beijing, 100142, China

  • Blacktown Hosital

    Blacktown, 02148, Australia

  • CER San Juan

    Buenos Aires, 01878, Argentina

  • CHA Centre Hospitalier de l Ardenne

    Libramont, B-6800, Belgium

  • CHR site de la Citadelle

    Liège, 04000, Belgium

  • CHU Louis Pradel

    Lyon, France

  • CHU Toulouse Hopital Larrey

    Toulouse, 31059, France

  • CHU UCL Namur

    Yvoir, 05530, Belgium

  • CHU de Poitier Pole regional de Cancerologie

    Poitiers, 86000, France

  • CHUO

    Ourense, 32005, Spain

  • Centre Hospitalier Jolimont-Lobbes

    Haine-Saint-Paul, 07100, Belgium

  • Centre Hospitalier Universitaire de Grenoble

    Grenoble, 38043, France

  • Centre Leon Berard

    Lyon, 69008, France

  • Centro de Investigacion Pergamino S.A.

    Pergamino, B2700CPM, Argentina

  • Centrul Medical Sanador

    Bucharest, 20125, Romania

  • Chang Gung Memorial Hospital CGMH - Kaohsiung Branch

    Niaosong, 00833, Taiwan

  • Charite - Universitaetsmedizin Berlin

    Berlin, 10117, Germany

  • Chi Mei Medical Center CMMC - Liouying Branch

    Tainan, 00736, Taiwan

  • Chung Shan Medical University Hospital

    Taichung, 00420, Taiwan

  • Chungbuk National University Hospital

    Cheongju-si, 28644, South Korea

  • Clinical Emergency Hospital

    Constanța, 900591, Romania

  • Cross Cancer Institute

    Edmonton, Alberta, T6G 1Z2, Canada

  • Crown Princess Mary Cancer Centre Westmead Hospital

    Sydney, 2145, Australia

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02115, United States

  • E-Da Hospital

    Kaohsiung City, 00824, Taiwan

  • Erasmus MC

    Amsterdam, 3000 CA, Netherlands

  • Evangelische Lungenklinik Berlin

    Berlin, 13125, Germany

  • FDI Clinical Research

    San Juan, 00927, Puerto Rico

  • Federal State Budgetary Institution - N.N. Blokhin National Medical Research Center of Oncology

    Moscow, 115478, Russia

  • Flinders Medical Centre

    Bedford Park, 05042, Australia

  • Florida Cancer Specialists

    Tallahassee, Florida, 32308, United States

  • Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico

    Milan, 20122, Italy

  • Fondazione IRCCS Istituto Nazionale Tumori

    Milan, 20133, Italy

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    Roma, 00168, Italy

  • Ft. Wayne Medical Oncology and Hematology

    Fort Wayne, Indiana, 46804, United States

  • Fudan University Shanghai Cancer Center

    Henan, 450008, China

  • Fujita Health University Hospital

    Toyoake, 470-1192, Japan

  • Gaston Martinengo

    Rosario, S2000, Argentina

  • Gustav Roussy Cancer Campus Grand Paris

    Villejuif, 94805, France

  • Harbin Medical University Cancer Hospital

    Heilongjiang, 150081, China

  • Henan Cancer Hospital

    Shanghai Sheng, 200032, China

  • Hopital Foch

    Sureesnes, 92150, France

  • Hopital Jean Minjoz

    Besançon, 25030, France

  • Hopital Pontchaillou

    Rennes, 35000, France

  • Hopitaux Universitaire de Strasbourg

    Strasbourg, 67098, France

  • Hospital Civil de Guadalajara Fray Antonio Alcalde

    Guadalajara, 44280, Mexico

  • Hospital Clinic i Provincial de Barcelona

    Barcelona, 08036, Spain

  • Hospital Clinico Universitario Lozano Bleza

    Zaragoza, 50009, Spain

  • Hospital General Universitario de Valencia

    Valencia, 46014, Spain

  • Hospital Medica Sur Tlalpan

    Mexico City, 14050, Mexico

  • Hospital Nossa Senhora da Conceição

    Porto Alegre, 91350-200, Brazil

  • Hospital Puerte de Hierro de Majadahonda

    Madrid, 28222, Spain

  • Hospital Regional Universitario Málaga

    Málaga, 29010, Spain

  • Hospital Sao Lucas da Pucrs

    Porto Alegre, 90610-000, Brazil

  • Hospital Universitari i Politecnic La Fe

    Valencia, 46026, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, 28041, Spain

  • Hospital Universitario Fundacion Jimenez Diaz

    Madrid, 28040, Spain

  • Hospital Universitario Jose Eleuterio Gonzalez

    Monterrey, 64460, Mexico

  • Hospital Universitario Vall d'Hebron

    Barcelona, 80350, Spain

  • Hospital Universitario de Valme

    Seville, 41014, Spain

  • Hospital Virgen Macarena

    Seville, 41007, Spain

  • Hospital de Base de Sao Jose do Rio Preto

    São José do Rio Preto, 15090-000, Brazil

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, 08025, Spain

  • Hubei Cancer Hospital

    Hubei, 430079, China

  • Hunan Cancer Hospital

    Changsha, China

  • Hyogo Cancer Center

    Akashi, 673-8558, Japan

  • ICON Cancer Centre Farrer Park Hospital

    Singapore, 217562, Singapore

  • II Klinika Chorob Pluc i Gruzlicy

    Bialystok, 15-276, Poland

  • IKF Krankenhaus Nordwest

    Frankfurt am Main, 60488, Germany

  • IRCCS Istituto Europeo di Oncologia

    Milan, 20141, Italy

  • Inselspital Universitätsspital Bern

    Bern, 3010, Switzerland

  • Instituicao de Fisioterapeutas Ocupacionais

    Roma, RM00144, Italy

  • Institut Curie

    Paris, 75248, France

  • Institute of Oncology Hadassah Moscow

    Moscow, Russia

  • Instituto Nacional de Cancer-INCA

    Rio de Janeiro, 20231-050, Brazil

  • Instituto de OncologÃÂ-a de Rosario

    Rosario, S2000KZE, Argentina

  • Instituto do Cancer do Ceara - ICC

    Fortaleza, 60430-230, Brazil

  • Institutul Oncologic Profesor Doctor Alexandru Trestioreanu

    Bucharest, 022328, Romania

  • Ironwood Cancer and Research Center

    Chandler, Arizona, 85224, United States

  • Isala Klinieken

    Harderwijk, 3844 DG, Netherlands

  • Jiamusi Cancer Tuberculosis Hospital

    Heilongjiang, 154007, China

  • Jiangsu Province Hospital

    Nanjing, China

  • Kadlec Clinic Hematology and Oncology

    Kennewick, Washington, 99336, United States

  • Kanazawa University Hospital

    Kanazawa, 920-8641, Japan

  • Kangbuk Samsung Hospital

    Seoul, 03181, South Korea

  • Kansai Medical University Hospital

    Hirakata, 573-1191, Japan

  • Kantonsspital St. Gallen

    Sankt Gallen, 9007, Switzerland

  • Karmanos Cancer Institute

    Detroit, Michigan, 48201, United States

  • Kindai University Hospital

    Ōsaka-sayama, 589-8511, Japan

  • Klinikum Traunstein

    Traunstein, Germany

  • Klinikverbund Allgäu

    Kempten, 87439, Germany

  • Kursk Regional Clinical Oncology Dispensary

    Kursk, 305524, Russia

  • Kyoto University Hospital

    Kyoto, 606-8507, Japan

  • Kyungpook National University Chilgok Hospital

    Daegu, 41404, South Korea

  • Kyushu University Hospital

    Fukuoka, 812-8582, Japan

  • LLC MSCH "Klinitsist"

    Novosibirsk, 630099, Russia

  • LinKou Chang Gung Memorial Hospital

    Taoyuan, 333, Taiwan

  • Linyi Cancer Hospital

    Hangzhou, 310003, China

  • Lungenklinik Hemer

    Hemer, 58675, Germany

  • MUHC-Glen Site and MUHC Research Institute

    Montreal, Quebec, H4A 3J1, Canada

  • Macquarie Hospital

    North Ryde, 02109, Australia

  • Magodent Sp. z.o.o Szpital Elblaska

    Warsaw, 01-748, Poland

  • Maria Sklodowska-Curie National Research Institute of Oncology

    Warsaw, 02-781, Poland

  • Med Polonia Sp. z o.o.

    Poznan, 60-693, Poland

  • Medizinische Klinik V

    Standort Gießen, Germany

  • Memorial Healthcare System- Memorial Cancer Institute

    Hollywood, Florida, 33021, United States

  • Meridian Hematology and Oncology

    Manahawkin, New Jersey, 08050, United States

  • Messino Cancer Centers

    Asheville, North Carolina, 28806, United States

  • Montefiore Medical Center

    The Bronx, New York, 10461, United States

  • Ms Pneumed

    Lublin, 20-090, Poland

  • N.N. Petrov Research Institute of Oncology

    Saint Petersburg, 197758, Russia

  • NHO Hokkaido Cancer Center

    Shiroishi, 003-0804, Japan

  • NHO Shikoku Cancer Center

    Matsuyama, 791-0280, Japan

  • National Cancer Center Hospital

    Tokyo, 104-0045, Japan

  • National Cancer Center Hospital East

    Kashiwa, 277-8577, Japan

  • National Cancer Centre Singapore

    Singapore, 169610, Singapore

  • National Cheng Kung University Hospital NCKUH

    Tainan, 00704, Taiwan

  • National Taiwan University Hospital NTUH

    Taipei, 00100, Taiwan

  • Niigata Cancer Center Hospital

    Chūōku, 951-8566, Japan

  • Northwest Medical Specialties

    Tacoma, Washington, 98405, United States

  • Northwestern University

    Chicago, Illinois, 60611, United States

  • Oddział Onkologii Wojewódzki Szpital Specjalistyczny Słupsk

    Słupsk, 76-200, Poland

  • Okayama University Hospital

    Okayama, 36927, Japan

  • Onco Clinic Consult SA

    Craiova, 200103, Romania

  • OncoCare Cancer Centre - Gleneagles Medical Centre Location

    Singapore, 258499, Singapore

  • Oncolab SRL

    Craiova, 200385, Romania

  • OptumCare Cancer Care

    Las Vegas, Nevada, 89106, United States

  • Orlando Health

    Orlando, Florida, 32806, United States

  • Orszagos Koranyi TBC es Pulmonologiai Intezet

    Budapest, 01121, Hungary

  • Osaka City General Hospital

    Osaka, 534-0021, Japan

  • Osaka International Cancer Institute

    Osaka, 541-8567, Japan

  • PIH Health

    Whittier, California, 90602, United States

  • Prince of Wales Hospital / The Chinese University of Hong Kong

    Hong Kong, 99999, Hong Kong

  • Queen Mary Hospital

    Hong Kong, 999077, Hong Kong

  • Roger Williams Medical Center

    Providence, Rhode Island, 02908, United States

  • SC Oncomed SRL

    Timișoara, 300425, Romania

  • SC Oncopremium Team SRL

    Baia Mare, 430291, Romania

  • SP Zespol Gruzlicy i Chorob Pluc

    Olsztyn, 10-357, Poland

  • Saitama Cancer Center

    Saitama, 362-0806, Japan

  • Saitama Medical University International Medical Center

    Hidaka, 350-1298, Japan

  • Samsung Medical Center

    Seoul, 06351, South Korea

  • San Peregrino Cancer Center

    Aguascalientes, 20230, Mexico

  • Sarah Cannon Research Institute

    Nashville, Tennessee, 37203, United States

  • Sendai Kousei Hospital

    Sendai, 980-0873, Japan

  • Seoul National University Boramae Medical Center

    Seoul, 07061, South Korea

  • Seoul National University Bundang Hospital

    Seongnam-si, 13620, South Korea

  • Sf Nectarie Oncology Center

    Craiova, 200347, Romania

  • Shanghai Chest Hospital

    Shanghai, China

  • Shizuoka Cancer Center

    Nagaizumi-chō, 411-8777, Japan

  • Sir Run Run Shaw Hospital Zhejiang University School of Medicine

    Zhejiang, 310016, China

  • Southern Medical Day Care Centre

    Wollongong, 02500, Australia

  • St. Jansdal Ziekenhuis

    Rotterdam, 3015 CD, Netherlands

  • St. Joseph Heritage Healthcare

    Anaheim, California, 92835, United States

  • St. Vincents Hospital The Catholic University of Korea

    Gyeonggi-do, 16247, South Korea

  • Stadtspital Waid ; Triemli, Site Triemli - clinic for Medical oncology &amp; hematology

    Zurich, 8063, Switzerland

  • Sunnbrook Health Sciences Centre

    Toronto, Ontario, ON M4N 3M5, Canada

  • Szent Borbala Korhaz

    Tatabánya, 02800, Hungary

  • Szpital Specjalistyczny w Prabutach Sp. z o.o.

    Prabuty, 82-550, Poland

  • Szpitale Pomorskie Sp.zo.o

    Gdynia, 81-519, Poland

  • Taichung Veterans General Hospital

    Taichung, 40705, Taiwan

  • The Cancer Institute Hospital of JFCR

    Kōtoku, 135-8550, Japan

  • The Catholic University of Korea, Seoul St. Marys Hospital

    Seoul, 06591, South Korea

  • The Center for Cancer and Blood Disorders

    Fort Worth, Texas, 76104, United States

  • The Christie Hospital

    Manchester, M20 4BX, United Kingdom

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Shandong, 276000, China

  • The First Affiliated Hospital of Zhejiang University

    Hangzou, 310022, China

  • The James Cook University Hospital

    Middlesbrough, TS4 3BW, United Kingdom

  • The Oncology Institute of Hope and Innovation

    Glendale, California, 91204, United States

  • Thoraxklinik Heidelberg gGmbH

    Heidelberg, 69126, Germany

  • Tianjin Medical University Cancer Institute and Hospital

    Tianjin, 300060, China

  • Tokushima University Hospital

    Tokushima, 770-8503, Japan

  • Tolna Megyei Balassa Janos Korhaz

    Tolna, Hungary

  • Tudogyogyintezet Torokbalint

    Törökbálint, H-2045, Hungary

  • UCLA

    Los Angeles, California, 90095, United States

  • Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology

    Wuhan, 43002, China

  • Universitaet zu Koeln - Uniklinik Koeln

    Cologne, 50937, Germany

  • Universitaetsklinikum Freiburg

    Freiburg im Breisgau, 79106, Germany

  • University College Hospital

    London, NW1 2BU, United Kingdom

  • University Headache Clinic LLC

    Moscow, 121467, Russia

  • University Health Network - Princess Margaret Hospital

    Toronto, Ontario, M5G0A3, Canada

  • University Hospital of Nantes - Thoracic Oncology

    Nantes, 44000, France

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio, 44106, United States

  • University of California San Diego

    La Jolla, California, 92093, United States

  • University of Chicago

    Chicago, Illinois, 60637, United States

  • University of Virginia Health System

    Charlottesville, Virginia, 22903, United States

  • Utah Cancer Specialists

    Salt Lake City, Utah, 84106, United States

  • Uzsoki Utcai Korhaz

    Budapest, 1145, Hungary

  • Virginia Cancer Specialist

    Fairfax, Virginia, 22031, United States

  • VitaMed LLC

    Moscow, 129515, Russia

  • Vseobecna Fakultni Nemocnice VFN

    Prague, 12800, Czechia

  • West China Hospital, Sichuan University

    Sichuan Province, China

  • Xiangya Hospital central south university

    Changsha, China

  • Yonsei University Health System - Severance Hospital

    Seoul, 03722, South Korea

  • Zhejiang Cancer Hospital

    Shanxi, 710061, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.